Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
February 16, 2024 08:00 ET
|
Autonomix Medical, Inc.
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, Feb. ...
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
February 14, 2024 08:05 ET
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate...
Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain
February 06, 2024 08:50 ET
|
Autonomix Medical, Inc.
First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer On track to commence enrollment in Q1 2024 THE WOODLANDS,...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event
February 01, 2024 08:35 ET
|
Autonomix Medical, Inc.
Live moderated webcast with members of the Autonomix management team on Wednesday, February 7th at 10:00 AM ET THE WOODLANDS, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc....
Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
January 31, 2024 08:45 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio
January 30, 2024 12:00 ET
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...
Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
January 30, 2024 09:05 ET
|
Autonomix Medical, Inc.
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS,...
Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ
January 29, 2024 08:05 ET
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE)...
Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
January 26, 2024 16:05 ET
|
Autonomix Medical, Inc.
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...